DiaMedica Therapeutics (NASDAQ:DMAC) Given Buy Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of DiaMedica Therapeutics (NASDAQ:DMAC) in a research report sent to investors on Friday morning,Benzinga reports. The firm currently has a $7.00 target price on the stock.

Separately, Oppenheimer reaffirmed an “outperform” rating and issued a $6.00 target price on shares of DiaMedica Therapeutics in a research report on Friday, August 16th.

DiaMedica Therapeutics Stock Up 3.5 %

NASDAQ DMAC opened at $4.15 on Friday. The firm has a market capitalization of $177.46 million, a PE ratio of -7.41 and a beta of 1.46. The stock’s 50 day moving average is $4.30 and its 200 day moving average is $3.59. DiaMedica Therapeutics has a twelve month low of $2.14 and a twelve month high of $4.95.

Institutional Trading of DiaMedica Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of DMAC. Vanguard Group Inc. boosted its stake in shares of DiaMedica Therapeutics by 26.3% in the first quarter. Vanguard Group Inc. now owns 1,013,522 shares of the company’s stock worth $2,807,000 after acquiring an additional 211,351 shares during the period. Magnolia Capital Advisors LLC bought a new position in shares of DiaMedica Therapeutics in the 2nd quarter valued at about $87,000. Blue Trust Inc. purchased a new stake in shares of DiaMedica Therapeutics during the third quarter worth about $185,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of DiaMedica Therapeutics in the 3rd quarter valued at $40,000. Finally, Geode Capital Management LLC raised its stake in DiaMedica Therapeutics by 29.6% in the 3rd quarter. Geode Capital Management LLC now owns 306,958 shares of the company’s stock worth $1,286,000 after acquiring an additional 70,070 shares during the last quarter. 10.12% of the stock is owned by hedge funds and other institutional investors.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.